Top

BMC Cancer

Published in:

Open Access 01-12-2018 | Research article

Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy

Authors: Robert Knoerl, Edie Weller, Barbara Halpenny, Donna Berry

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

Impaired physical function due to chemotherapy-induced peripheral neuropathy (CIPN) symptoms may lead to diminished quality of life. However, even with the knowledge of the effects of CIPN on physical function, clinicians infrequently assess and manage CIPN. Interventions that prioritize the early identification of CIPN to provide prompt treatment may reduce the impact of CIPN on physical function. The purpose of this paper is to compare self-reported physical function in individuals receiving neurotoxic chemotherapy between Electronic Symptom Assessment-Cancer (ESRA-C) intervention group (e.g., opportunity for symptom screening, self-care recommendations, communication coaching, and symptom tracking) and control group participants (i.e., electronic assessment alone). Secondary outcomes include pain intensity, sensory/motor CIPN, depression, fatigue, and insomnia.

Methods

The data used in this paper are a subset of a randomized controlled trial that examined the impact of the ESRA-C intervention on symptom distress in individuals receiving cancer treatment. Since the interest in this analysis is on the effects of neurotoxic chemotherapy on physical function, subjects were included if they received platinum and/or taxane-based chemotherapy and completed the baseline and end-of-treatment measures. Participants completed standardized questionnaires of physical function, CIPN, fatigue, depression, pain intensity, and insomnia prior to treatment, 3–6 weeks after treatment initiation, and after the completion of treatment. Changes in mean scores are compared between groups using linear mixed models adjusting for age.

Results

Intervention group participants reported significantly less reduction in physical functioning (baseline: 87.4/100; end-of-treatment: 84.5/100) relative to the control (baseline: 90.2/100; end-of-treatment: 81.8/100) (p = 0.011). For secondary measures, significantly less depression (p = 0.005) was observed in the intervention group as compared to the control, but otherwise, there were no between-group differences. Among participants who received high cumulative doses of neurotoxic chemotherapy, the intervention group reported significantly less severe sensory (p = 0.007) and motor CIPN (p = 0.039) relative to the control.

Conclusion

Use of the ESRA-C intervention led to less reduction in physical function in comparison to the control in individuals receiving neurotoxic chemotherapy. Further research is needed to confirm our findings and to identify how electronic symptom assessment technology may mediate physical function preservation.

Trial registration

ClinicalTrials.Gov NCT00852852. Registered 27 February 2009.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. https://doi.org/10.3322/caac.21387.CrossRefPubMed

Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82:51–77.CrossRef

Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155:2461–70.CrossRef

Fukuda Y, Li Y, Segal RA. A mechanistic understanding of axon degeneration in chemotherapy-induced peripheral neuropathy. Front Neurosci. 2017;11:481. https://doi.org/10.3389/fnins.2017.00481.CrossRefPubMedPubMedCentral

Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol (Madr). 2015;54:587–91. https://doi.org/10.3109/0284186X.2014.995775.CrossRef

Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 2016;73:860. https://doi.org/10.1001/jamaneurol.2016.0383.CrossRef

Monfort SM, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton MJ, et al. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Res Treat. 2017;164:69–77. https://doi.org/10.1007/s10549-017-4230-8.CrossRefPubMedPubMedCentral

Simon NB, Danso MA, Alberico TA, Basch E, Bennett A V. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice. Qual Life Res. 2017;1–10. doi:https://doi.org/10.1007/s11136-017-1635-0.CrossRef

Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, et al. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2017;35:2604–12. https://doi.org/10.1200/JCO.2016.71.3552.CrossRefPubMedPubMedCentral

10.

Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract. 2012;2012:913848. https://doi.org/10.1155/2012/913848.CrossRefPubMedPubMedCentral

11.

Zanville NR, Nudelman KNH, Smith DJ, Von Ah D, McDonald BC, Champion VL, et al. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment. Support Care Cancer. 2016;24:4779–89. https://doi.org/10.1007/s00520-016-3329-5.CrossRefPubMedPubMedCentral

12.

Beijers A, Mols F, Dercksen W, Driessen C, Vreugdenhil G. Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy. J community Support Oncol. 2014;12:401–6. https://doi.org/10.12788/jcso.0086.CrossRefPubMed

13.

Smith EML, Campbell G, Tofthagen C, Kottschade L, Collins ML, Warton C, et al. Nursing knowledge, practice patterns, and learning preferences regarding chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2014;41:669–79. https://doi.org/10.1188/14.ONF.669-679.CrossRefPubMed

14.

Alberti P, Rossi E, Cornblath DR, Merkies ISJ, Postma TJ, Frigeni B, et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol. 2014;25:257–64. https://doi.org/10.1093/annonc/mdt409.CrossRefPubMed

15.

Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–67.CrossRef

16.

Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:1941–67.CrossRef

17.

Schwenk M, Grewal GS, Holloway D, Muchna A, Garland L, Najafi B. Interactive sensor-based balance training in older cancer patients with chemotherapy-induced peripheral neuropathy: a randomized controlled trial. Gerontology. 2016;62:553–63. https://doi.org/10.1159/000442253.CrossRef

18.

Zimmer P, Trebing S, Timmers-Trebing U, Schenk A, Paust R, Bloch W, et al. Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. Support Care Cancer. 2018;26:615–24. https://doi.org/10.1007/s00520-017-3875-5.CrossRefPubMed

19.

Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, et al. National comprehensive cancer network task force report: management of neuropathy in cancer. J Natl Compr Cancer Netw. 2009;7(Suppl 5):S1–S26.

20.

Knoerl R, Dudley WN, Smith G, Bridges C, Kanzawa-Lee G, Lavoie Smith EM. Pilot testing a web-based system for the assessment and management of chemotherapy-induced peripheral neuropathy. CIN Comput Informatics Nurs. 2016;1. doi:https://doi.org/10.1097/CIN.0000000000000320.PubMed

21.

Knoerl R, Lee D, Yang J, Bridges C, Kanzawa-Lee G, Lita Smith G, et al. Examining the impact of a web-based intervention to promote patient activation in chemotherapy-induced peripheral neuropathy assessment and management. J Cancer Educ. 2017;1–9. doi:https://doi.org/10.1007/s13187-017-1200-0.CrossRef

22.

Kolb NA, Smith AG, Singleton JR, Beck SL, Howard D, Dittus K, et al. Chemotherapy-related neuropathic symptom management: a randomized trial of an automated symptom-monitoring system paired with nurse practitioner follow-up. Support Care Cancer. 2018;26:1607–15. https://doi.org/10.1007/s00520-017-3970-7.

23.

Berry DL, Hong F, Halpenny B, Partridge AH, Fann JR, Wolpin S, et al. Electronic self-report assessment for cancer and self-care support: results of a multicenter randomized trial. J Clin Oncol. 2014;32:199–205.CrossRef

24.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.

25.

Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A, et al. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels; 2001.

26.

Atkinson TM, Stover AM, Storfer DF, Saracino RM, D’Agostino TA, Pergolizzi D, et al. Patient-reported physical function measures in cancer clinical trials. Epidemiol Rev. 2017;39:59–70. https://doi.org/10.1093/epirev/mxx008.CrossRef

27.

Miaskowski C, Barsevick A, Berger A, Casagrande R, Grady PA, Jacobsen P, et al. Advancing Symptom Science Through Symptom Cluster Research: Expert Panel Proceedings and Recommendations. J Natl Cancer Inst. 2017;109:djw253.CrossRef

28.

Dong ST, Costa DSJ, Butow PN, Lovell MR, Agar M, Velikova G, et al. Symptom clusters in advanced Cancer patients: an empirical comparison of statistical methods and the impact on quality of life. J Pain Symptom Manag. 2016;51:88–98. https://doi.org/10.1016/j.jpainsymman.2015.07.013.CrossRef

29.

Hwang K-H, Cho O-H, Yoo Y-S. Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life. Eur J Oncol Nurs. 2016;21:215–22. https://doi.org/10.1016/j.ejon.2015.10.007.CrossRefPubMed

30.

Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, Hagen S, et al. The EORTC Core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer. 1995;31:2260–3. https://doi.org/10.1016/0959-8049(95)00296-0.CrossRef

31.

Bjordal K, de Graeff A, Fayers P, Hammerlid E, van Pottelsberghe C, Curran D, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. Eur J Cancer. 2000;36:1796–807. https://doi.org/10.1016/S0959-8049(00)00186-6.CrossRef

32.

Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005;41:1135–9.CrossRef

33.

Smith EML, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: the reliability and validity of the european organization for research and treatment of cancer QLQ-CIPN20 questionnaire. Qual Life Res. 2013;22:2787–99.CrossRef

34.

Eckhoff L, Knoop AS, Jensen M-B, Ejlertsen B, Ewertz M. Risk of docetaxel-induced peripheral neuropathy among 1,725 danish patients with early stage breast cancer. Breast Cancer Res Treat. 2013;142:109–18. https://doi.org/10.1007/s10549-013-2728-2.CrossRef

35.

Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14(Suppl 4):iv45–54. https://doi.org/10.1093/neuonc/nos203.CrossRefPubMedPubMedCentral

36.

Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol. 2017;8:86. https://doi.org/10.3389/fphar.2017.00086.CrossRefPubMedPubMedCentral

37.

Pace A, Nisticò C, Cuppone F, Bria E, Galiè E, Graziano G, et al. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clin Breast Cancer. 2007;7:550–4. https://doi.org/10.3816/CBC.2007.n.010.CrossRefPubMed

38.

Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA. 1999;282:1737–44.CrossRef

39.

Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13. https://doi.org/10.1046/j.1525-1497.2001.016009606.x.CrossRefPubMedPubMedCentral

40.

Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9–19. https://doi.org/10.1016/j.pain.2004.09.012.CrossRefPubMed

41.

Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manag. 2011;41:1073–93.CrossRef

42.

Li L, Liu X, Herr K. Postoperative pain intensity assessment: a comparison of four scales in Chinese adults. Pain Med. 2007;8:223–34.CrossRef

43.

R Development Core Team. R: A language and environment for statistical computing. 2017. https://www.r-project.org.

44.

Pinheiro J, Bates D, DebRoy S, Sarkar D, R Development Core Team. nlme: Linear and Nonlinear Mixed Effects Models (R Package Version 3.1–137). 2018. https://cran.r-project.org/package=nlme.

45.

Giesinger JM, Kuijpers W, Young T, Tomaszewski KA, Friend E, Zabernigg A, et al. Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain. Health Qual Life Outcomes. 2016;14:87. https://doi.org/10.1186/s12955-016-0489-4.CrossRefPubMedPubMedCentral

46.

Maringwa J, Quinten C, King M, Ringash J, Osoba D, Coens C, et al. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol. 2011;22:2107–12. https://doi.org/10.1093/annonc/mdq726.CrossRefPubMed

47.

Knoerl R, Bridges C, Smith G, Yang J, Kanzawa-Lee G, Smith E. Chemotherapy-induced peripheral neuropathy: use of an electronic care planning system to improve adherence to recommended assessment and management practices. Clin J Oncol Nurs. 2018;22:E134–40. https://doi.org/10.1188/18.CJON.E134-E140.CrossRefPubMed

48.

Tofthagen C, Visovsky CM, Hopgood R. Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management. Clin J Oncol Nurs. 2013;17:138–44. https://doi.org/10.1188/13.CJON.138-144.CrossRefPubMedPubMedCentral

49.

Tofthagen C, Kip KE, Passmore D, Loy I, Berry DL. Usability and acceptability of a web-based program for chemotherapy-induced peripheral neuropathy. Comput Inform Nurs. 2016;34:322–9. https://doi.org/10.1097/CIN.0000000000000242.CrossRefPubMed

50.

Imai K, Keele L, Tingley D. A general approach to causal mediation analysis. Psychol Methods. 2010;15:309–34.CrossRef

51.

Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care. 2004;42:1194–201.CrossRef

52.

Lenz ER, Pugh LC, Milligan RA, Gift A, Suppe F. The middle-range theory of unpleasant symptoms: an update. ANS Adv Nurs Sci. 1997;19:14–27.CrossRef

53.

Berry DL, Blonquist TM, Patel RA, Halpenny B, McReynolds J. Exposure to a patient-centered, Web-based intervention for managing cancer symptom and quality of life issues: impact on symptom distress. J Med Internet Res. 2015;17:e136. https://doi.org/10.2196/jmir.4190.CrossRefPubMedPubMedCentral

54.

Greenlee H, Hershman DL, Shi Z, Kwan ML, Ergas IJ, Roh JM, et al. BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study. J Natl Cancer Inst. 2017;109:djw206. https://doi.org/10.1093/jnci/djw206.CrossRefPubMed

55.

Zimmer P, Trebing S, Timmers-Trebing U, Schenk A, Paust R, Bloch W, et al. Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. Support Care Cancer. 2017;1–10. doi:https://doi.org/10.1007/s00520-017-3875-5.CrossRef

56.

Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer. 2017. https://doi.org/10.1007/s00520-017-4013-0.CrossRef

57.

Kerns RD, Sellinger J, Goodin BR. Psychological treatment of chronic pain. Annu Rev Clin Psychol. 2011;7:411–34. https://doi.org/10.1146/annurev-clinpsy-090310-120430.CrossRefPubMed

58.

Kwekkeboom KL, Abbott-Anderson K, Cherwin C, Roiland R, Serlin RC, Ward SE. Pilot randomized controlled trial of a patient-controlled cognitive-behavioral intervention for the pain, fatigue, and sleep disturbance symptom cluster in Cancer. J Pain Symptom Manag. 2012;44:810–22. https://doi.org/10.1016/j.jpainsymman.2011.12.281.CrossRef

59.

Carlson LE, Zelinski E, Toivonen K, Flynn M, Qureshi M, Piedalue K-A, et al. Mind-body therapies in Cancer: what is the latest evidence? Curr Oncol Rep. 2017;19:67. https://doi.org/10.1007/s11912-017-0626-1.CrossRefPubMed

60.

Knoerl R, Smith EML, Barton DL, Williams DA, Holden JE, Krauss JC, et al. Self-guided online cognitive behavioral strategies for chemotherapy-induced peripheral neuropathy: a multicenter, pilot, randomized, Wait-List Controlled, Trial. J Pain. 2018;19:382–94. https://doi.org/10.1016/j.jpain.2017.11.009.CrossRefPubMed

61.

McCorkle R. The measurement of symptom distress. Semin Oncol Nurs. 1987;3:248–56.CrossRef

Title: Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy
Authors: Robert Knoerl
Edie Weller
Barbara Halpenny
Donna Berry
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-5093-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2018

Thymoma with an isolated splenic metastasis eight years after extended thymectomy: a case report

The identification of H3F3A mutation in giant cell tumour of the clivus and the histological diagnostic algorithm of other clival lesions permit the differential diagnosis in this location

Quality assurance target for community-based breast cancer screening in China: a model simulation

Local ablation or radioembolization of colorectal cancer metastases: comorbidities or older age do not affect overall survival

BB-Cl-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway

Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer